Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03300284 · ClinicalTrials.gov registry record
Decision Making and Psychological Outcomes in Low-Risk Papillary Thyroid Cancer
A clinical trial of Thyroid Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 186
- Enrollment target
- 5
- Study locations
NCT03300284: Completed study of Thyroid Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03300284 is a study of Thyroid Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 186 participants, below the 278-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (33% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03300284, a study of Thyroid Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 186 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is being done to understand the decision-making process regarding management choice in low-risk papillary thyroid cancer.
Primary Outcome
Patients will complete a pre-visit questionnaire and the patient-physician interaction during the visit will be recorded and subjected to qualitative analysis for extraction of variables representing the presence of elements of shared decision making and strength of physician influence.
Conditions Studied
Interventions
- BEHAVIORAL Questionnaires
Study Locations (5)
New York
- MAIMONIDES MEDICAL CENTER (Data collection only) - Brooklyn
- Memorial Sloan Kettering Cancer Center - New York
Connecticut
- Hartford Healthcare (Data Collection) - Hartford
New Jersey
- Memorial Sloan Kettering Monmouth (Consent and Follow up) - Middletown
Pennsylvania
- Lehigh Valley Health Network - Allentown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2017-08-07 |
| Est. Completion | 2023-07-13 |
What the finished NCT03300284 record still lists
NCT03300284 is an observational study that tracks outcomes without assigning an intervention. The registered 186 participants enrollment target is mid-sized for trials with a published cap, below the 278-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (33% lower).
The record links to 1 condition, with Thyroid Cancer appearing as the primary indexed condition, and to 1 intervention - of which Questionnaires is the first listed.
NCT03300284 lists 5 locations in 4 states (New York, Connecticut, New Jersey).
Frequently Asked Questions
What is clinical trial NCT03300284 about?
NCT03300284 is a clinical study titled "Decision Making and Psychological Outcomes in Low-Risk Papillary Thyroid Cancer". This study is being done to understand the decision-making process regarding management choice in low-risk papillary thyroid cancer.
What is the current status of trial NCT03300284?
This trial is currently completed. The enrollment target is 186 participants. The study started on 2017-08-07. Estimated completion is 2023-07-13.
What conditions does trial NCT03300284 study?
This clinical trial studies the following conditions: Thyroid Cancer.
What interventions are being tested in trial NCT03300284?
The interventions under investigation include: Questionnaires (BEHAVIORAL).
Who is sponsoring clinical trial NCT03300284?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03300284 being conducted?
This trial has 5 study locations across Connecticut, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03300284's enrollment target sits among peer trials
186 13th of 46 higher than 34 of 46 other Thyroid Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thyroid Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
RECRUITING · Phase 2
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer
RECRUITING
-
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03567889 · 186 participants · Phase 3
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- NCT05281471 · 186 participants · Phase 3
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- NCT05405595 · 186 participants · Phase 1
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- NCT05762107 · 186 participants · Phase 2
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI